{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:22:35Z","timestamp":1792790555084,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004784","name":"Novartis Stiftung\u00a0f\u00fcr\u00a0Medizinisch-Biologische Forschung","doi-asserted-by":"publisher","award":["22A038"],"award-info":[{"award-number":["22A038"]}],"id":[{"id":"10.13039\/501100004784","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sassella Foundation, grant numbers 19\/15 JOBST Award"},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["316340"],"award-info":[{"award-number":["316340"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ETH Zurich Open ETH project SKINTEGRITY.CH","id":[{"id":"https:\/\/ror.org\/05a28rw58","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Secondary lymphedema is a common sequel of oncologic surgery and presents a global health burden still lacking pharmacological treatment. The infiltration of the lymphedematous extremities with CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells influences lymphedema onset and emerges as a promising therapy target. Here, we show that the modulation of CD4\n                    <jats:sup>+<\/jats:sup>\n                    FOXP3\n                    <jats:sup>+<\/jats:sup>\n                    CD25\n                    <jats:sup>+<\/jats:sup>\n                    regulatory T (T\n                    <jats:sub>reg<\/jats:sub>\n                    ) cells upon anti-CTLA4 treatment protects against lymphedema development in patients with melanoma and in a mouse lymphedema model. A retrospective evaluation of a melanoma patient registry reveals that anti-CTLA4 reduces lymphedema risk; in parallel, anti-CTLA4 reduces edema and improves lymphatic function in a mouse-tail lymphedema model. This protective effect of anti-CTLA4 correlates with a systemic expansion of Tregs, both in the animal model and in patients with melanoma. Our data thus show that anti-CTLA4 with its lymphedema-protective and anti-tumor properties is a promising candidate for more diverse application in the clinics.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-55002-6","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T11:23:05Z","timestamp":1735557785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3+ Treg population"],"prefix":"10.1038","volume":"15","author":[{"given":"Stefan","family":"Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-3977","authenticated-orcid":false,"given":"Matiar","family":"Madanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3695-8264","authenticated-orcid":false,"given":"Patrick","family":"Turko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3250-7653","authenticated-orcid":false,"given":"Maija","family":"Hollm\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Tugues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"von Atzigen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Giovanoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lindenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7899-2850","authenticated-orcid":false,"given":"Cornelia","family":"Halin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5351-5054","authenticated-orcid":false,"given":"Michael","family":"Detmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5902-9420","authenticated-orcid":false,"given":"Mitchell","family":"Levesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5171-8237","authenticated-orcid":false,"given":"Epameinondas","family":"Gousopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"55002_CR1","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2012.41.8574","volume":"30","author":"ED Paskett","year":"2012","unstructured":"Paskett, E. D., Dean, J. A., Oliveri, J. M. & Harrop, J. P. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. J. Clin. Oncol. 30, 3726\u20133733 (2012).","journal-title":"J. Clin. Oncol."},{"key":"55002_CR2","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/archsurg.137.11.1253","volume":"137","author":"SM Beaulac","year":"2002","unstructured":"Beaulac, S. M., McNair, L. A., Scott, T. E., LaMorte, W. W. & Kavanah, M. T. Lymphedema and quality of life in survivors of early-stage breast cancer. Arch. Surg. 137, 1253\u20131257 (2002).","journal-title":"Arch. Surg."},{"key":"55002_CR3","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jamcollsurg.2013.12.041","volume":"218","author":"MS Cowher","year":"2014","unstructured":"Cowher, M. S. et al. Conservative axillary surgery in breast cancer patients undergoing mastectomy: long-term results. J. Am. Coll. Surg. 218, 819\u2013824 (2014).","journal-title":"J. Am. Coll. Surg."},{"key":"55002_CR4","doi-asserted-by":"publisher","first-page":"e664","DOI":"10.1016\/j.clbc.2022.01.013","volume":"22","author":"Y Lin","year":"2022","unstructured":"Lin, Y. et al. Manual lymphatic drainage for breast cancer-related lymphedema: a systematic review and meta-analysis of randomized controlled trials. Clin. Breast Cancer 22, e664\u2013e673 (2022).","journal-title":"Clin. Breast Cancer"},{"key":"55002_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/PRS.0000000000007783","volume":"147","author":"DW Chang","year":"2021","unstructured":"Chang, D. W. et al. Surgical treatment of lymphedema: a systematic review and meta-analysis of controlled trials. results of a consensus conference. Plast. Reconstr. Surg. 147, 975\u2013993 (2021).","journal-title":"Plast. Reconstr. Surg."},{"key":"55002_CR6","doi-asserted-by":"publisher","unstructured":"Li, C. Y., Kataru, R. P. & Mehrara, B. J. (2020) Histopathologic features of lymphedema: a molecular review. Int. J. Mol. Sci. 21, https:\/\/doi.org\/10.3390\/ijms21072546.","DOI":"10.3390\/ijms21072546"},{"key":"55002_CR7","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.jvsv.2021.09.004","volume":"10","author":"J Walker","year":"2022","unstructured":"Walker, J., Tanna, S., Roake, J. & Lyons, O. A systematic review of pharmacologic and cell-based therapies for treatment of lymphedema (2010-2021). J. Vasc. Surg. Venous Lymphat. Disord. 10, 966\u2013975 e961 (2022).","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"55002_CR8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41388-020-01539-x","volume":"40","author":"D Kong","year":"2021","unstructured":"Kong, D. et al. VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk. Oncogene 40, 964\u2013979 (2021).","journal-title":"Oncogene"},{"key":"55002_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1146\/annurev-immunol-032712-095937","volume":"31","author":"G Wick","year":"2013","unstructured":"Wick, G. et al. The immunology of fibrosis. Ann. Rev. Immunol. 31, 107\u2013135 (2013).","journal-title":"Ann. Rev. Immunol."},{"key":"55002_CR10","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1371\/journal.pmed.0030254","volume":"3","author":"R Tabibiazar","year":"2006","unstructured":"Tabibiazar, R. et al. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med. 3, e254 (2006).","journal-title":"PLoS Med."},{"key":"55002_CR11","doi-asserted-by":"publisher","unstructured":"Tian, W. et al. (2017) Leukotriene B4 antagonism ameliorates experimental lymphedema. Sci. Transl. Med. 9, https:\/\/doi.org\/10.1126\/scitranslmed.aal3920.","DOI":"10.1126\/scitranslmed.aal3920"},{"key":"55002_CR12","doi-asserted-by":"publisher","unstructured":"Rockson, S. G. et al. (2018) Pilot studies demonstrate the potential benefits of antiinflammatory therapy in human lymphedema. JCI Insight 3, https:\/\/doi.org\/10.1172\/jci.insight.123775.","DOI":"10.1172\/jci.insight.123775"},{"key":"55002_CR13","unstructured":"ULTRA. Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA). https:\/\/clinicaltrials.gov\/show\/NCT02700529."},{"key":"55002_CR14","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1096\/fj.12-222695","volume":"27","author":"T Avraham","year":"2013","unstructured":"Avraham, T. et al. Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema. FASEB J. 27, 1114\u20131126 (2013).","journal-title":"FASEB J."},{"key":"55002_CR15","doi-asserted-by":"publisher","first-page":"e89081","DOI":"10.1172\/jci.insight.89081","volume":"1","author":"E Gousopoulos","year":"2016","unstructured":"Gousopoulos, E. et al. Regulatory T cell transfer ameliorates lymphedema and promotes lymphatic vessel function. JCI Insight 1, e89081 (2016).","journal-title":"JCI Insight"},{"key":"55002_CR16","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jid.2015.12.001","volume":"136","author":"F Ogata","year":"2016","unstructured":"Ogata, F. et al. Excess lymphangiogenesis cooperatively induced by macrophages and CD4(+) T Cells drives the pathogenesis of lymphedema. J. Invest. Dermatol. 136, 706\u2013714 (2016).","journal-title":"J. Invest. Dermatol."},{"key":"55002_CR17","doi-asserted-by":"publisher","first-page":"e49940","DOI":"10.1371\/journal.pone.0049940","volume":"7","author":"JC Zampell","year":"2012","unstructured":"Zampell, J. C. et al. CD4(+) cells regulate fibrosis and lymphangiogenesis in response to lymphatic fluid stasis. PLoS ONE 7, e49940 (2012).","journal-title":"PLoS ONE"},{"key":"55002_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14345","volume":"8","author":"JC Gardenier","year":"2017","unstructured":"Gardenier, J. C. et al. Topical tacrolimus for the treatment of secondary lymphedema. Nat. Commun. 8, 14345 (2017).","journal-title":"Nat. Commun."},{"key":"55002_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4048\/jbc.2023.26.e2","volume":"26","author":"FC Gulmark Hansen","year":"2023","unstructured":"Gulmark Hansen, F. C., Jorgensen, M. G. & Sorensen, J. A. Treatment of breast cancer-related lymphedema with topical tacrolimus: a prospective, open-label, single-arm, phase II pilot trial. J. Breast Cancer 26, 46\u201359 (2023).","journal-title":"J. Breast Cancer"},{"key":"55002_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.trsl.2018.12.003","volume":"206","author":"CL Ly","year":"2019","unstructured":"Ly, C. L., Nores, G. D. G., Kataru, R. P. & Mehrara, B. J. T helper 2 differentiation is necessary for development of lymphedema. Transl. Res. 206, 57\u201370 (2019).","journal-title":"Transl. Res."},{"key":"55002_CR21","doi-asserted-by":"publisher","unstructured":"Mehrara, B. J. et al. (2021) Pilot study of Anti-Th2 immunotherapy for the treatment of breast cancer-related upper extremity lymphedema. Biology 10, https:\/\/doi.org\/10.3390\/biology10090934.","DOI":"10.3390\/biology10090934"},{"key":"55002_CR22","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei, S. C. et al. Distinct cellular mechanisms underlie Anti-CTLA-4 and Anti-PD-1 checkpoint blockade. Cell 170, 1120\u20131133 e1117 (2017).","journal-title":"Cell"},{"key":"55002_CR23","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.jaad.2017.03.022","volume":"77","author":"AA Grada","year":"2017","unstructured":"Grada, A. A. & Phillips, T. J. Lymphedema: pathophysiology and clinical manifestations. J. Am. Acad. Dermatol. 77, 1009\u20131020 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"55002_CR24","doi-asserted-by":"publisher","first-page":"e3431","DOI":"10.1097\/GOX.0000000000003431","volume":"9","author":"M Coriddi","year":"2021","unstructured":"Coriddi, M., Mehrara, B., Skoracki, R., Singhal, D. & Dayan, J. H. Immediate lymphatic reconstruction: technical points and literature review. Plast. Reconstr. Surg. Glob. Open 9, e3431 (2021).","journal-title":"Plast. Reconstr. Surg. Glob. Open"},{"key":"55002_CR25","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1245\/s10434-010-1203-0","volume":"17","author":"MB Faries","year":"2010","unstructured":"Faries, M. B. et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann. Surg. Oncol. 17, 3324\u20133329 (2010).","journal-title":"Ann. Surg. Oncol."},{"key":"55002_CR26","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.amjsurg.2015.08.014","volume":"210","author":"JF Friedman","year":"2015","unstructured":"Friedman, J. F. et al. Risk factors associated with lymphedema after lymph node dissection in melanoma patients. Am. J. Surg. 210, 1178\u20131184 (2015).","journal-title":"Am. J. Surg."},{"key":"55002_CR27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/intimm\/dxp072","volume":"21","author":"W Wang","year":"2009","unstructured":"Wang, W. et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25(Hi) regulatory T cells. Int. Immunol. 21, 1065\u20131077 (2009).","journal-title":"Int. Immunol."},{"key":"55002_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1084\/jem.192.2.303","volume":"192","author":"T Takahashi","year":"2000","unstructured":"Takahashi, T. et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303\u2013310 (2000).","journal-title":"J. Exp. Med."},{"key":"55002_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jid.2017.09.011","volume":"138","author":"GD Garcia Nores","year":"2018","unstructured":"Garcia Nores, G. D. et al. Regulatory T cells mediate local immunosuppression in lymphedema. J. Invest. Dermatol. 138, 325\u2013335 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"55002_CR30","doi-asserted-by":"publisher","first-page":"e1655","DOI":"10.1371\/journal.pntd.0001655","volume":"6","author":"LJ Wammes","year":"2012","unstructured":"Wammes, L. J. et al. Regulatory T cells in human lymphatic filariasis: stronger functional activity in microfilaremics. PLoS Negl. Trop. Dis. 6, e1655 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"55002_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","volume":"30","author":"SZ Josefowicz","year":"2012","unstructured":"Josefowicz, S. Z., Lu, L. F. & Rudensky, A. Y. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531\u2013564 (2012).","journal-title":"Annu. Rev. Immunol."},{"key":"55002_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2006.05.042","volume":"126","author":"Y Wu","year":"2006","unstructured":"Wu, Y. et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126, 375\u2013387 (2006).","journal-title":"Cell"},{"key":"55002_CR33","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.4049\/jimmunol.177.7.4376","volume":"177","author":"S Read","year":"2006","unstructured":"Read, S. et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J. Immunol. 177, 4376\u20134383 (2006).","journal-title":"J. Immunol."},{"key":"55002_CR34","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695\u20131710 (2013).","journal-title":"J. Exp. Med."},{"key":"55002_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","volume":"1","author":"MJ Selby","year":"2013","unstructured":"Selby, M. J. et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1, 32\u201342 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"55002_CR36","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","volume":"112","author":"E Romano","year":"2015","unstructured":"Romano, E. et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc. Natl Acad. Sci. USA 112, 6140\u20136145 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55002_CR37","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41422-018-0011-0","volume":"28","author":"X Du","year":"2018","unstructured":"Du, X. et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res. 28, 416\u2013432 (2018).","journal-title":"Cell Res."},{"key":"55002_CR38","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","volume":"33","author":"F Arce Vargas","year":"2018","unstructured":"Arce Vargas, F. et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 33, 649\u2013663 e644 (2018).","journal-title":"Cancer Cell"},{"key":"55002_CR39","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2007-11-125435","volume":"112","author":"B Kavanagh","year":"2008","unstructured":"Kavanagh, B. et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+T cells in a dose-dependent fashion. Blood 112, 1175\u20131183 (2008).","journal-title":"Blood"},{"key":"55002_CR40","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","volume":"16","author":"BC Carthon","year":"2010","unstructured":"Carthon, B. C. et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16, 2861\u20132871 (2010).","journal-title":"Clin. Cancer Res."},{"key":"55002_CR41","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1158\/1078-0432.CCR-11-0407","volume":"17","author":"RR Huang","year":"2011","unstructured":"Huang, R. R. et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin. Cancer Res. 17, 4101\u20134109 (2011).","journal-title":"Clin. Cancer Res."},{"key":"55002_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-016-0141-1","volume":"4","author":"J Retseck","year":"2016","unstructured":"Retseck, J. et al. Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J. Immunother. Cancer 4, 38 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"55002_CR43","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/1078-0432.CCR-08-0783","volume":"15","author":"A Ribas","year":"2009","unstructured":"Ribas, A. et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin. Cancer Res. 15, 390\u2013399 (2009).","journal-title":"Clin. Cancer Res."},{"key":"55002_CR44","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","volume":"25","author":"A Sharma","year":"2019","unstructured":"Sharma, A. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers. Clin. Cancer Res. 25, 1233\u20131238 (2019).","journal-title":"Clin. Cancer Res."},{"key":"55002_CR45","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1016\/j.cell.2021.05.027","volume":"184","author":"F Marangoni","year":"2021","unstructured":"Marangoni, F. et al. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. Cell 184, 3998\u20134015 e3919 (2021).","journal-title":"Cell"},{"key":"55002_CR46","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1189\/jlb.0208085","volume":"84","author":"C Brinster","year":"2008","unstructured":"Brinster, C. & Shevach, E. M. Costimulatory effects of IL-1 on the expansion\/differentiation of CD4+CD25+Foxp3+ and CD4+CD25+Foxp3- T cells. J. Leukoc. Biol. 84, 480\u2013487 (2008).","journal-title":"J. Leukoc. Biol."},{"key":"55002_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ccell.2022.11.014","volume":"41","author":"OS Blomberg","year":"2023","unstructured":"Blomberg, O. S. et al. IL-5-producing CD4(+) T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. Cancer Cell 41, 106\u2013123 e110 (2023).","journal-title":"Cancer Cell"},{"key":"55002_CR48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao, J. et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397\u2013404 e399 (2016).","journal-title":"Cell"},{"key":"55002_CR49","first-page":"2434","volume":"116","author":"Z Wang","year":"2006","unstructured":"Wang, Z. et al. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+CD25- T cells to CD4+ Tregs. J. Clin. Invest. 116, 2434\u20132441 (2006).","journal-title":"J. Clin. Invest."},{"key":"55002_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43554-y","volume":"15","author":"A Zamora","year":"2024","unstructured":"Zamora, A. et al. 15-Lipoxygenase promotes resolution of inflammation in lymphedema by controlling T(reg) cell function through IFN-beta. Nat. Commun. 15, 221 (2024).","journal-title":"Nat. Commun."},{"key":"55002_CR51","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"N Nosengo","year":"2016","unstructured":"Nosengo, N. Can you teach old drugs new tricks? Nature 534, 314\u2013316 (2016).","journal-title":"Nature"},{"key":"55002_CR52","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1016\/j.biomaterials.2013.03.034","volume":"34","author":"ST Proulx","year":"2013","unstructured":"Proulx, S. T. et al. Use of a PEG-conjugated bright near-infrared dye for functional imaging of rerouting of tumor lymphatic drainage after sentinel lymph node metastasis. Biomaterials 34, 5128\u20135137 (2013).","journal-title":"Biomaterials"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55002-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55002-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55002-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T12:05:33Z","timestamp":1735560333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55002-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55002"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55002-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3330226\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"6 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NL acts as Scientific Advisor and Consultant for Medical Microinstruments (MMI). RD has intermittent, project-focused consulting and\/or advisory relationships with Novartis, Merck Sharp & Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer, Simcere and touchIME outside the submitted work. All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10784"}}